The primary end point was local recurrence-free survival, with overall survival, patterns of failure and toxicity as secondary endpoints.
Thus, within two decades, improved pharmacological treatment and device technology increased survival of heart failure patients by 1 year, but 65% of all heart failure patients still died within 5 years.
Despite the improvement of cardiovascular outcome and survival of heart failure patients through strategies of classical pharmacological treatment (e.g., the use of beta-blockers and angiotensin-converting enzyme (ACE) inhibitors), such therapies are ultimately unable to prevent further progression of the disease itself [ 10].
Although classical pharmacologic treatment strategies have improved cardiovascular outcome and survival of heart failure patients [ e.g. using beta-blockers and ACE (angiotensin (Ang -converting enzyme) inhibitors], the prognosis of Ang -convertingduals renzyme poor winhibitors] million cardiovascular deathe in the Europrognosisn per year.
Therefore, 291 patients were analysed for survival and patterns of failure.
Li et al. showed that VNS markedly improved the long-term survival of chronic heart failure rats through the prevention of pumping failure, remodeling, and increasing contractility [ 60].
Randomized studies of the survival of acute renal failure patients in intensive care according to the type of membrane used [60 75] do not yield a definitive conclusion because of the small total number of patients studied (under 650).
Given the absolute necessity for proper protein folding, secretion, and transmembrane insertion, the multi-faceted nature of the ER stress responses, and the role of autophagy in survival of transient ER failure, it is not surprising that multiple parallel ER-autophagy pathways might be in play.
We identified published studies investigating long-term survival of cancer, heart failure and stroke patients after diagnosis in different developed countries using electronic search strategies.
Randomized studies of the survival of acute renal failure patients in intensive care according to the type of membrane used [ 60– 75] do not yield a definitive conclusion because of the small total number of patients studied (under 650).
